NCT07118813 Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment
| NCT ID | NCT07118813 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Condition | Renal Cell Carcinoma (Kidney Cancer) |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-08 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2025-08 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective observational cohort study (AI-Kidney-Prognosis), aiming to non-invasively predict the clinical outcomes in renal cell carcinoma patients after surgical treatment using radiomics-based AI models, thereby assisting clinical decision-making and personalized follow-up strategies.
Eligibility Criteria
Inclusion Criteria: 1. Patients were treated for renal cell carcinoma in Wuhan Union Hospital from August 2025 to August 2026; 2. Aged \> 18 years old; 3. At least one abdominal CT scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of renal cell carcinoma. Exclusion Criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than renal cell carcinoma; 4. Unclear pathological diagnosis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07118813 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Cell Carcinoma (Kidney Cancer). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07118813 currently recruiting?
Yes, NCT07118813 is actively recruiting participants. Contact the research team at yanglian@hust.edu.cn for enrollment information.
Where is the NCT07118813 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07118813 clinical trial?
NCT07118813 is sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.